

Special Issue

Biomarkers for Oncogenic Viruses

Message from the Guest Editors

Biomarkers have become key tools for detecting cancers caused by viruses and lesions. Besides the detection of viruses and their products, host proteins that are altered in their expression are beneficial for discriminating virally caused cancers from other cancers. Emerging technologies are expanding our abilities to detect precancerous lesions and cancers associated with human tumor viruses and to monitor their recurrence and tumor microenvironment, including liquid biopsies, single cell and/or spatial transcriptomics/proteomics, highly sensitive in situ hybridization techniques, and high-dimensional multiplex flow cytometry, among others. These emerging tools are useful at detecting not only biomarkers for virus-associated cancers at an early stage and at diagnosis, but also biomarkers for recurrence and patient response to therapies. We welcome primary papers and reviews that help move the field of biomarkers of oncogenic viruses forward.

Guest Editors

Prof. Dr. Paul F. Lambert

McArdle Laboratory for Cancer Research, University of Wisconsin, Madison, WI, USA

Dr. Wei Wang

McArdle Laboratory for Cancer Research, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA

Deadline for manuscript submissions

closed (30 November 2023)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.6
Indexed in PubMed



mdpi.com/si/172759

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.6
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.2 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).